URLC10/CDCA1/KOC1 derived peptide vaccine(The University of Tokyo Hospital)(URLC10/CDCA1/KOC1 derived peptide vaccine(The University of Tokyo Hospital))

概要

基本信息

药物类型

合成肽疫苗、治疗性疫苗

别名-

靶点-

作用机制-

治疗领域

肿瘤消化系统疾病

在研适应症

食管癌

非在研适应症-

原研机构

The University of Tokyo Hospital

在研机构

The University of Tokyo Hospital

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 URLC10/CDCA1/KOC1 derived peptide vaccine(The University of Tokyo Hospital) 相关的临床试验

NCT01069640 / Completed临床1期IIT

Phase I Study of Cancer Vaccine Therapy Using Epitope Peptide Restricted to HLA-A*02 (URLC10) in Patients With Non-small Cell Lung Cancer Refractory to Standard Therapy

The purpose of this study is to evaluate the safety, tolerability, immune response and clinical efficacies of HLA-A*0201 or HLA-A*0206 restricted epitope peptides URLC10 emulsified with Montanide ISA 51 for advanced non-small cell lung cancers.

开始日期2010-02-01

申办/合作机构

Shiga University

[+1]

NCT00753844 / Completed临床1期IIT

Tumor Vaccine Therapy Against Advanced Esophageal Cancer Using HLA-A*2402 Restricted Epitope Peptides Drived From URLC10

The purpose of this study it to evaluate the safety and immune response of peptides (URLC10) emulsified with Montanide ISA51 in treating patients with unresectable, advanced or recurrent esophageal cancer.

开始日期2006-11-01

申办/合作机构